LIU; Pingrong
Patent Applications and Registrations
Patent applications and USPTO patent grants for LIU; Pingrong.The latest application filed is for "heteroaryl carboxamide compounds as inhibitors of ripk2".
- LIU; Pingrong - Southbury CT
| Patent | Date |
|---|---|
| Heteroaryl Carboxamide Compounds As Inhibitors Of Ripk2 App 20220081437 - LIU; Pingrong ; et al. | 2022-03-17 |
| Substituted benzamides as RIPK2 inhibitors Grant 11,130,754 - Liu , et al. September 28, 2 | 2021-09-28 |
| Heteroaryl Carboxamide Compounds As Inhibitors Of Ripk2 App 20190048000 - LIU; Pingrong ; et al. | 2019-02-14 |
| Substituted benzamides as RIPK2 inhibitors Grant 10,138,241 - Liu , et al. Nov | 2018-11-27 |
| Substituted benzamides as RIPK2 inhibitors Grant 10,138,222 - Cui , et al. Nov | 2018-11-27 |
| Pyridine And Pyrazine Compounds As Inhibitors Of Ripk2 App 20180072703 - CUI; Jianwen ; et al. | 2018-03-15 |
| Heteroaryl Carboxamide Compounds As Inhibitors Of Ripk2 App 20180072717 - LIU; Pingrong ; et al. | 2018-03-15 |
| Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof Grant 8,741,897 - Bekkali , et al. June 3, 2 | 2014-06-03 |
| Pyrazolopiperidine compounds as CCR1 receptor antagonists Grant 8,546,442 - Betageri , et al. October 1, 2 | 2013-10-01 |
| Pyridinyl compounds useful as intermediates Grant 8,338,610 - Kuzmich , et al. December 25, 2 | 2012-12-25 |
| Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists App 20120322790 - BETAGERI; Rajashekhar ; et al. | 2012-12-20 |
| Pyrazole compounds as CCR1 antagonists Grant 8,293,917 - Cook , et al. October 23, 2 | 2012-10-23 |
| Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof Grant 8,268,859 - Harcken , et al. September 18, 2 | 2012-09-18 |
| Pyridinyl Compounds Useful As Intermediates App 20120136158 - COOK; Brian Nicholas ; et al. | 2012-05-31 |
| Azaindazole Compounds As CCR1 Receptor Antagonists App 20120035370 - COOK; Brian Nicholas ; et al. | 2012-02-09 |
| Azaindazole compounds as CCR1 receptor antagonists Grant 8,063,065 - Cook , et al. November 22, 2 | 2011-11-22 |
| Pyrazole Compounds As CCR1 Antagonists App 20110230521 - Cook; Brian Nicholas ; et al. | 2011-09-22 |
| Azaindazole Compounds As CCR1 Receptor Antagonists App 20110086846 - COOK; Brian Nicholas ; et al. | 2011-04-14 |
| Azaindazole compounds as CCR1 receptor antagonists Grant 7,879,873 - Cook , et al. February 1, 2 | 2011-02-01 |
| Azaindazole Compounds As CCR1 Receptor Antagonists App 20100093724 - COOK; Brian Nicholas ; et al. | 2010-04-15 |
| Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof App 20090325988 - Harcken; Christian ; et al. | 2009-12-31 |
| Heterocyclic compounds Grant 7,115,644 - Barbosa, Jr. , et al. October 3, 2 | 2006-10-03 |
| Anti aromatase compounds pharmaceutical compositions and uses thereof App 20060030608 - Nelson; Richard More ; et al. | 2006-02-09 |
| Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof App 20050176706 - Bekkali, Younes ; et al. | 2005-08-11 |
| Heterocyclic compounds App 20040192748 - Barbosa, Antonio Jose del Moral JR. ; et al. | 2004-09-30 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 